Related Experiment Videos
Global surgical experience with the Acorn cardiac support device
Mehmet C Oz1, Wolfgang F Konertz, Franz X Kleber
1Columbia-Presbyterian Medical Center, 117 Ft Washington Ave, New York, NY 10032, USA. mco2@columbia.edu
The Journal of Thoracic and Cardiovascular Surgery
|October 21, 2003
Summary
The CorCap cardiac support device shows promise for treating dilated cardiomyopathy, demonstrating safety and improved heart function in patients. Further clinical trials are ongoing to confirm these findings.
Area of Science:
- Cardiology
- Biomedical Engineering
- Cardiac Surgery
Background:
- Dilated cardiomyopathy leads to left ventricular remodeling and dysfunction.
- Surgical intervention is an option, but reducing mechanical stress is crucial.
- The Acorn CorCap device offers end-diastolic support to mitigate these issues.
Purpose of the Study:
- To review the global clinical safety and feasibility of the Acorn CorCap cardiac support device.
- To assess the device's impact on cardiac function and remodeling.
- To evaluate patient outcomes and adverse events.
Main Methods:
- The Acorn CorCap device was implanted in over 130 patients with dilated cardiomyopathy.
- Initial safety and feasibility studies included 48 patients, with 33 undergoing concomitant cardiac surgery.
- Data collected included implantation time, intraoperative measurements, and 24-month follow-up.
Main Results:
- No device-related intraoperative complications were observed.
- Actuarial survival was 73% at 12 months and 68% at 24 months.
- Patients showed decreased ventricular dimensions, improved ejection fraction, and better New York Heart Association class.
Conclusions:
- The CorCap device demonstrates safety in patients with dilated cardiomyopathy.
- The device appears to improve cardiac function and reverse remodeling.
- Randomized clinical trials are currently in progress globally.